RAPIBLYK 280 mg/1
landiolol · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · AOP Orphan Pharmaceuticals GmbH
RAPIBLYK is a injection, powder, lyophilized, for solution containing landiolol at 280 mg/1, taken intravenous. Manufactured by AOP Orphan Pharmaceuticals GmbH.
Key Facts
- Brand Name
- RAPIBLYK
- Generic Name
- landiolol
- NDC Code (Product)
84381-110- Manufacturer
- AOP Orphan Pharmaceuticals GmbH
- Strength
- 280 mg/1
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- NDA217202
- Marketing Start
- 08/07/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is RAPIBLYK used for?
RAPIBLYK contains landiolol. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is RAPIBLYK a controlled substance?
RAPIBLYK is not classified as a controlled substance by the DEA.
What is the generic name for RAPIBLYK?
The generic name for RAPIBLYK is landiolol. There are no other listed brand versions of landiolol.
What is the NDC code for RAPIBLYK 280 mg/1?
The NDC (National Drug Code) for RAPIBLYK 280 mg/1 is 84381-110, listed by AOP Orphan Pharmaceuticals GmbH.
Other RAPIBLYK Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)